Lipigon Pharmaceuticals AB Capital Reinvestment Ratio

Latest as of March 2020: 0.39x

Lipigon Pharmaceuticals AB capital reinvestment ratio. Lipigon Pharmaceuticals AB (LPGO) has a Capital Reinvestment Ratio of 0.39x as of March 2020, meaning it reinvests 0% of its operating cash flow (Skr309.00K) in capital expenditures (Skr119.00K). Check total reinvestment intensity of Lipigon Pharmaceuticals AB to assess the company's total reinvestment commitment from operating cash flow.

Capital Reinvestment Ratio

0.39x

Capex / Operating Cash Flow

Operating Cash Flow

Skr309.00K

SEK

Capital Expenditures

Skr119.00K

SEK

Data as of

Mar 2020

Most recent filing

Lipigon Pharmaceuticals AB Capital Reinvestment Ratio by Year (None–None)

Lipigon Pharmaceuticals AB capital reinvestment ratio by year from None to None. For the full cash flow conversion analysis, see cash efficiency ratio of Lipigon Pharmaceuticals AB.

Year	Reinvestment Ratio	Operating CF (SEK)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow